Zydus Cadila receives approvals from the DCGI to start Phase Ill Clinical Trial of ZyCoV-D

Zydus Cadila, an innovation driven global pharmaceutical company focused on discovering and developing NCEs, Novel Biologicals, Biosimilars and Vaccines, announced that it will be starting Phase III clinical trials of it plasmid DNA vaccine to prevent COVID-19, ZyCoV-D after having received permissions from the DCGI.

The company will now be initiating Phase III clinical trial in around 30,000 volunteers. ZyCoV-D was found to be safe, well tolerated and immunogenic in the Phase I/II clinical trials.

The Phase II study of the vaccine ZyCoV-D had been conducted in over 1000 healthy adult volunteers as part of the adaptive Phase I/II dose escalation, multi-centric, randomized, double-blind placebo controlled study. The vaccine was found to be safe and elicit a strong immunogenic response. The trial has reviewed by an independent Data Safety Monitoring Board (DSMB) and reports were submitted to Central Drugs Standard Control Organisation (CDSCO) regularly for the update on safety outcome.

Speaking on the development, Mr. Pankaj R. Patel, Chairman of the Zydus Group said, "We are reaching a critical milestone in our vaccine development programme and towards our goal of helping people fight the pandemic with an indigenously discovered, safe and efficacious vaccine. The launch of the Phase 3 trial will determine the efficacy of our vaccine in preventing COVID-19 which continues to pose a major threat, the world over."

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.478.5 as compared to the previous close of Rs. 476.3. The total number of shares traded during the day was 90135 in over 1121 trades.

The stock hit an intraday high of Rs. 482.8 and intraday low of 477. The net turnover during the day was Rs. 43227471.

Source : Equity Bulls

Keywords